<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H08ACB3D6E9424CBFB74273B7AA826052" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 4531 IH: Support for Patients and Communities Reauthorization Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-07-11</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 4531</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230711">July 11, 2023</action-date><action-desc><sponsor name-id="G000558">Mr. Guthrie</sponsor> (for himself and <cosponsor name-id="K000382">Ms. Kuster</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committees on <committee-name committee-id="HJU00">the Judiciary</committee-name>, and <committee-name committee-id="HED00">Education and the Workforce</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To reauthorize certain programs that provide for opioid use disorder prevention, recovery, and treatment, and for other purposes.</official-title></form><legis-body id="H8C617D4ED2374E12B3B0DE504D8CCBC9" style="OLC"><section id="H9F3306F1400F492ABD8562FB8F43E30E" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Support for Patients and Communities Reauthorization Act</short-title></quote>.</text></section><section id="HD73E675959624A3794D58EEDA5B97AAA"><enum>2.</enum><header>Table of contents</header><text display-inline="no-display-inline">The table of contents for this Act is as follows:</text><toc container-level="legis-body-container" quoted-block="no-quoted-block" lowest-level="section" regeneration="yes-regeneration" lowest-bolded-level="division-lowest-bolded"><toc-entry idref="H9F3306F1400F492ABD8562FB8F43E30E" level="section">Sec. 1. Short title.</toc-entry><toc-entry idref="HD73E675959624A3794D58EEDA5B97AAA" level="section">Sec. 2. Table of contents.</toc-entry><toc-entry idref="HEEBBD39AD573495EAA0D9EDD1B7FFCD8" level="title">Title I—Public Health</toc-entry><toc-entry idref="H5848AF0B41F145389349687C86C267AB" level="section">Sec. 101. Monitoring and education regarding infections associated with illicit drug use and other risk factors.</toc-entry><toc-entry idref="H1A17523A0A7A4D11800FEC3812FD5FF4" level="section">Sec. 102. Preventing overdoses of controlled substances.</toc-entry><toc-entry idref="H81A435157E1E48E3A1BDBB18C38ED790" level="section">Sec. 103. Residential treatment programs for pregnant and postpartum women.</toc-entry><toc-entry idref="HD68A5ED242FC497591BAA8AA9381AB1F" level="section">Sec. 104. First responder training.</toc-entry><toc-entry idref="H6AA2668CB8D34C7D8630EEF878EB8BC6" level="section">Sec. 105. Building communities of recovery.</toc-entry><toc-entry idref="H00385FF4194446E98B21AC267CF8FF58" level="section">Sec. 106. National Peer-Run Training and Technical Assistance Center for Addiction Recovery Support.</toc-entry><toc-entry idref="H1DF1D74A5B2344028FF6403F313743BA" level="section">Sec. 107. Comprehensive opioid recovery centers.</toc-entry><toc-entry idref="HA8ED90694EF843238D94E1F246561758" level="section">Sec. 108. Grants to address the problems of persons who experience violence related stress.</toc-entry><toc-entry idref="H2DB3651441314A6CA46157E258A0836C" level="section">Sec. 109. Mental and behavioral health education and training grants.</toc-entry><toc-entry idref="H4A0C643E736B4A1FA1D0BFB1DEB4B741" level="section">Sec. 110. Loan repayment program for the substance use disorder treatment workforce.</toc-entry><toc-entry idref="H54C5A32A13B24ACDA0D940CA0B875626" level="section">Sec. 111. Pilot program for public health laboratories to detect fentanyl and other synthetic opioids.</toc-entry><toc-entry idref="H44B800A99CFB4EE5818B6A7FB167EE1D" level="section">Sec. 112. Monitoring and reporting of child, youth, and adult trauma.</toc-entry><toc-entry idref="HCC83A384499D415D83FCC5EF3E202321" level="section">Sec. 113. Task force to develop best practices for trauma-informed identification, referral, and support.</toc-entry><toc-entry idref="H8B34E36B4DBA4C9CBF18227865432A7D" level="section">Sec. 114. Treatment, recovery, and workforce support grants.</toc-entry><toc-entry idref="H695287BD7E0048EF95D1B7DFF2D5038C" level="section">Sec. 115. Grant program for State and Tribal response to opioid use disorders.</toc-entry><toc-entry idref="HE922CA0D0AEB4271BC49D237B48B59FD" level="section">Sec. 116. References to opioid overdose reversal agents in HHS grant programs.</toc-entry><toc-entry idref="H72237F8A325841CD95A18CDF20D4B538" level="section">Sec. 117. Addressing other concurrent substance use disorders through grant program for State and Tribal response to opioid use disorders.</toc-entry><toc-entry idref="HEB669F4F64694637B785AC03DDAD089F" level="section">Sec. 118. Providing for a study on the effects of remote monitoring on individuals who are prescribed opioids.</toc-entry><toc-entry idref="H77197CC1DFFA4964B8F5BB7714B88534" level="title">Title II—Controlled Substances</toc-entry><toc-entry idref="HF5B4BB05D8C044D6A4E86366279AA9BC" level="section">Sec. 201. Delivery of certain substances by a pharmacy to an administering practitioner.</toc-entry><toc-entry idref="H52ED9FA9D3014132AC29F099A828BB26" level="section">Sec. 202. Reviewing the scheduling of approved products containing a combination of buprenorphine and naloxone.</toc-entry><toc-entry idref="H76CA7AAB298A4E95B9AC07AA01C70084" level="section">Sec. 203. Combating illicit xylazine.</toc-entry><toc-entry idref="HCA49109F12A8494AA315A98CA7AD5A0B" level="section">Sec. 204. Technical corrections.</toc-entry><toc-entry idref="HC591B937F13549E49190DE790096CD77" level="title">Title III—Medicaid</toc-entry><toc-entry idref="HF9A9409399EF4A129A7298457C98DA2A" level="section">Sec. 301. Extending requirement for State Medicaid plans to provide coverage for medication-assisted treatment.</toc-entry><toc-entry idref="HF28D0703FBF149158705AAD741A2CD95" level="section">Sec. 302. Expanding required reports on T–MSIS substance use disorder data to include mental health condition data.</toc-entry><toc-entry idref="H39132D27809E43499EAD9EB0350021AE" level="section">Sec. 303. Monitoring prescribing of antipsychotic medications.</toc-entry></toc></section><title id="HEEBBD39AD573495EAA0D9EDD1B7FFCD8"><enum>I</enum><header>Public Health</header><section id="H5848AF0B41F145389349687C86C267AB"><enum>101.</enum><header>Monitoring and education regarding infections associated with illicit drug use and other risk factors</header><text display-inline="no-display-inline">Section 317N of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247b-15">42 U.S.C. 247b–15</external-xref>) is amended—</text><paragraph id="H9598A7700AF4471EBC88B1D9D66BD60A"><enum>(1)</enum><text>in the section heading, by striking <quote><header-in-text level="section" style="OLC">Surveillance and</header-in-text></quote> and inserting <quote><header-in-text level="section" style="OLC">Monitoring and</header-in-text></quote>; and</text></paragraph><paragraph id="H8AAE9C0EB203430EBEC354071C8288EF"><enum>(2)</enum><text>in subsection (d), by striking <quote>fiscal years 2019 through 2023</quote> and inserting <quote>fiscal years 2024 through 2028</quote>.</text></paragraph></section><section id="H1A17523A0A7A4D11800FEC3812FD5FF4"><enum>102.</enum><header>Preventing overdoses of controlled substances</header><subsection id="H91F1F96DC0F445B396CDE722EE6D04AB"><enum>(a)</enum><header>Evidence-Based prevention grants</header><text display-inline="yes-display-inline">Section 392A(a)(2)(D) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/280b-1">42 U.S.C. 280b–1(a)(2)(D)</external-xref>) is amended by inserting after <quote>new and emerging public health crises</quote> the following: <quote>, such as the fentanyl crisis,</quote>.</text></subsection><subsection id="H46653996A2A246F4A2A9A0CF55DED41C"><enum>(b)</enum><header>Authorization of appropriations</header><text>Section 392A(e) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/280b-1">42 U.S.C. 280b–1(e)</external-xref>) is amended by striking <quote>$496,000,000 for each of fiscal years 2019 through 2023</quote> and inserting <quote>$505,579,000 for each of fiscal years 2024 through 2028</quote>.</text></subsection></section><section id="H81A435157E1E48E3A1BDBB18C38ED790"><enum>103.</enum><header>Residential treatment programs for pregnant and postpartum women</header><text display-inline="no-display-inline">Section 508(s) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290bb-1">42 U.S.C. 290bb–1(s)</external-xref>) is amended by striking <quote>$29,931,000 for each of fiscal years 2019 through 2023</quote> and inserting <quote>$38,931,000 for each of fiscal years 2024 through 2028</quote>.</text></section><section id="HD68A5ED242FC497591BAA8AA9381AB1F"><enum>104.</enum><header>First responder training</header><text display-inline="no-display-inline">Section 546(h) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290ee-1">42 U.S.C. 290ee–1(h)</external-xref>) is amending by striking <quote>$36,000,000 for each of fiscal years 2019 through 2023</quote> and inserting <quote>$56,000,000 for each of fiscal years 2024 through 2028</quote>.</text></section><section id="H6AA2668CB8D34C7D8630EEF878EB8BC6"><enum>105.</enum><header>Building communities of recovery</header><text display-inline="no-display-inline">Section 547(f) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290ee-2">42 U.S.C. 290ee–2(f)</external-xref>) is amended by striking <quote>$5,000,000 for each of fiscal years 2019 through 2023</quote> and inserting <quote>$16,000,000 for each of fiscal years 2024 through 2028</quote>. </text></section><section id="H00385FF4194446E98B21AC267CF8FF58"><enum>106.</enum><header>National Peer-Run Training and Technical Assistance Center for Addiction Recovery Support</header><text display-inline="no-display-inline">Section 547A(e) of the Public Health Service Act (42 U.S.C. 290ee–2a(e)) is amended by striking <quote>$1,000,000 for each of fiscal years 2019 through 2023</quote> and inserting <quote>$2,000,000 for each of fiscal years 2024 through 2028</quote>.</text></section><section id="H1DF1D74A5B2344028FF6403F313743BA"><enum>107.</enum><header>Comprehensive opioid recovery centers</header><subsection id="H4A267660FD2F4BE2963A1A22C9FBAA86"><enum>(a)</enum><header>Reauthorization</header><text>Section 552(j) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290ee-7">42 U.S.C. 290ee–7(j)</external-xref>) is amended by striking <quote>2019 through 2023</quote> and inserting <quote>2024 through 2028</quote>.</text></subsection><subsection id="HCA7709494C1D429C84D184579AA0D52D"><enum>(b)</enum><header>Documentation for evidence of capacity To carry out required activities</header><text>Section 552(d) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290ee-7">42 U.S.C. 290ee–7(d)</external-xref>) is amended by adding at the end the following: </text><quoted-block style="OLC" id="HD2935CA1934047F7BB678962D8508421" display-inline="no-display-inline"><paragraph id="H36CE180E4FD545ECA994CA912A2CD9C8"><enum>(3)</enum><header>Documentation</header><subparagraph id="HCD8B9D1160BF41E88A7DFDF0FC1A86D1"><enum>(A)</enum><header>In general</header><text>Evidence required to be provided under paragraph (1) may be provided through a letter of intent from partner agencies or other relevant documentation (as defined by the Secretary).</text></subparagraph><subparagraph id="HD0A86C86B45C4E7A97FE3121DD8B1E24"><enum>(B)</enum><header>Partner agency defined</header><text display-inline="yes-display-inline">In this paragraph, the term <term>partner agency</term> means a non-governmental organization or other public or private entity—</text><clause id="HFF2718B00DCA4053BBD643F34E450803"><enum>(i)</enum><text>the primary purpose of which is the delivery of mental health or substance use disorder treatment services; and</text></clause><clause id="HE794CD52C2D54ADEA9F6F2F5C93B9302"><enum>(ii)</enum><text display-inline="yes-display-inline">with which the applicant coordinates to provide the full continuum of treatment services (as specified in subsection (g)(1)(B)) that the applicant is unable to offer on site.</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HB63DA7D3EEC64C249AFD5C9D48138254"><enum>(c)</enum><header>Center activities carried out through third parties</header><text display-inline="yes-display-inline">Section 552(g) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290ee-7">42 U.S.C. 290ee–7(g)</external-xref>) is amended in the matter preceding paragraph (1) by striking <quote>Each Center shall</quote> and all that follows through <quote>subsection (f):</quote> and inserting the following: <quote>Each Center shall, at a minimum, carry out the activities specified in this subsection directly, through referral, or through contractual arrangements. If a Center elects to carry out such activities through contractual arrangements, the Secretary may issue guidance on best practices to ensure that the Center is capable of carrying out such activities, including carrying out such activities through technology-enabled collaborative learning and capacity building models described in subsection (f) and coordinating the full continuum of treatment services specified in subparagraph (B). Such activities include the following:</quote>. </text></subsection></section><section id="HA8ED90694EF843238D94E1F246561758"><enum>108.</enum><header>Grants to address the problems of persons who experience violence related stress</header><text display-inline="no-display-inline">Section 582(j) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290hh-1">42 U.S.C. 290hh–1(j)</external-xref>) is amended by striking <quote>$63,887,000 for each of fiscal years 2019 through 2023</quote> and inserting <quote>$93,887,000 for each of fiscal years 2024 through 2028</quote>.</text></section><section id="H2DB3651441314A6CA46157E258A0836C"><enum>109.</enum><header>Mental and behavioral health education and training grants</header><text display-inline="no-display-inline">Section 756(f) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/294e-1">42 U.S.C. 294e–1(f)</external-xref>) is amended by striking <quote>fiscal years 2023 through 2027</quote> and inserting <quote>fiscal years 2024 through 2028</quote>.</text></section><section id="H4A0C643E736B4A1FA1D0BFB1DEB4B741"><enum>110.</enum><header>Loan repayment program for the substance use disorder treatment workforce</header><text display-inline="no-display-inline">Section 781(j) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/295h">42 U.S.C. 295h(j)</external-xref>) is amended by striking <quote>$25,000,000 for each of fiscal years 2019 through 2023</quote> and inserting <quote>$40,000,000 for each of fiscal years 2024 through 2028</quote>.</text></section><section id="H54C5A32A13B24ACDA0D940CA0B875626"><enum>111.</enum><header>Pilot program for public health laboratories to detect fentanyl and other synthetic opioids</header><text display-inline="no-display-inline">Section 7011(d) of the SUPPORT for Patients and Communities Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-10">42 U.S.C. 247d–10(d)</external-xref>) is amended by striking <quote>fiscal years 2019 through 2023</quote> and inserting <quote>fiscal years 2024 through 2028</quote>.</text></section><section id="H44B800A99CFB4EE5818B6A7FB167EE1D"><enum>112.</enum><header>Monitoring and reporting of child, youth, and adult trauma</header><text display-inline="no-display-inline">Section 7131(e) of the SUPPORT for Patients and Communities Act (<external-xref legal-doc="usc" parsable-cite="usc/42/242t">42 U.S.C. 242t(e)</external-xref>) is amended by striking <quote>$2,000,000 for each of fiscal years 2019 through 2023</quote> and inserting <quote>$9,000,000 for each of fiscal years 2024 through 2028</quote>.</text></section><section id="HCC83A384499D415D83FCC5EF3E202321"><enum>113.</enum><header>Task force to develop best practices for trauma-informed identification, referral, and support</header><text display-inline="no-display-inline">Section 7132 of the SUPPORT for Patients and Communities Act (<external-xref legal-doc="public-law" parsable-cite="pl/115/271">Public Law 115–271</external-xref>) is amended—</text><paragraph id="HD679F93C71D342EA975A3FDCF424E759"><enum>(1)</enum><text>in subsection (g)—</text><subparagraph id="H0052E96AC4414D86999CC04002227DFA"><enum>(A)</enum><text display-inline="yes-display-inline">in paragraph (1), by striking <quote>and</quote> at the end;</text></subparagraph><subparagraph id="H93EB58C5B5654E80BFCF2BF9D136ACEA"><enum>(B)</enum><text>in paragraph (2), by striking the period at the end and inserting <quote>; and</quote>; and</text></subparagraph><subparagraph id="H5272408D27D24051A3D3D4EE5D0A4934"><enum>(C)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" id="H5E1FF4CF9D6A4FFFA05A740D6FD003EC" display-inline="no-display-inline"><paragraph id="H3B5ACE29C9AA4FAE94FF96F01A9C57C7"><enum>(3)</enum><text display-inline="yes-display-inline">additional reports and updates to existing reports, as necessary.</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="HE673D5648E7F4AC4A1C399FF673D1C27"><enum>(2)</enum><text>by striking subsection (i).</text></paragraph></section><section commented="no" display-inline="no-display-inline" section-type="subsequent-section" id="H8B34E36B4DBA4C9CBF18227865432A7D"><enum>114.</enum><header display-inline="yes-display-inline">Treatment, recovery, and workforce support grants</header><text display-inline="no-display-inline">Section 7183 of the SUPPORT for Patients and Communities Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290ee-8">42 U.S.C. 290ee–8</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="HD9D6D639834D4860A72C31F53A0806E1"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (b), by inserting <quote>each</quote> before <quote>for a period</quote>;</text></paragraph><paragraph id="H4A908EB74341422DAB3E032C79808D2B"><enum>(2)</enum><text>by amending subsection (c)(2) to read as follows:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H728CF69571484D729179C8A8F388E4A1"><paragraph commented="no" display-inline="no-display-inline" id="HF448E7A3443C4CFF8EE85A6A893AB638"><enum>(2)</enum><header display-inline="yes-display-inline">Rates</header><text display-inline="yes-display-inline">The rates described in this paragraph are the following:</text><subparagraph commented="no" display-inline="no-display-inline" id="H54DAD5FFC6FD44AD8DB667528826F45D"><enum>(A)</enum><text>The amount by which the average rate of drug overdose deaths in the State, adjusted for age, for the period of 5 calendar years for which there is available data, including if necessary provisional data, immediately preceding the grant cycle (which shall be the period of calendar years 2018 through 2022 for the first grant cycle following the enactment of the <short-title>Support for Patients and Communities Reauthorization Act</short-title>) is above the average national overdose mortality rate, as determined by the Director of the Centers for Disease Control and Prevention, for the same period.</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H5C8B542D4D2A4C0CB28BE83E3B208F1D"><enum>(B)</enum><text>The amount by which the average rate of unemployment for the State, based on data provided by the Bureau of Labor Statistics, for the period of 5 calendar years for which there is available data, including if necessary provisional data, immediately preceding the grant cycle (which shall be the period of calendar years 2018 through 2022 for the first grant cycle following the enactment of the <short-title>Support for Patients and Communities Reauthorization Act</short-title>) is above the national average for the same period.</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H32FBB825DFD541ECAB6FD96708239F84"><enum>(C)</enum><text>The amount by which the average rate of labor force participation in the State, based on data provided by the Bureau of Labor Statistics, for the period of 5 calendar years for which there is available data, including if necessary provisional data, immediately preceding the grant cycle (which shall be the period of calendar years 2018 through 2022 for the first grant cycle following the enactment of the <short-title>Support for Patients and Communities Reauthorization Act</short-title>) is below the national average for the same period.</text></subparagraph></paragraph><after-quoted-block>;</after-quoted-block></quoted-block></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HF488DF5A820F485B966AC4DE746E3958"><enum>(3)</enum><text>in subsection (g)—</text><subparagraph commented="no" display-inline="no-display-inline" id="HC3865BC899A849E5A60F60DD59C3CBB5"><enum>(A)</enum><text display-inline="yes-display-inline">in paragraphs (1) and (3), by redesignating subparagraphs (A) and (B) as clauses (i) and (ii), respectively, and adjusting the margins accordingly;</text></subparagraph><subparagraph id="H4B43F46751AB4ADCBE460298DCE8565A"><enum>(B)</enum><text>by redesignating paragraphs (1) through (3) as subparagraphs (A) through (C), respectively, and adjusting the margins accordingly;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H1ACC6096F5E349F29D409589124CD3A1"><enum>(C)</enum><text>by striking <quote>An entity</quote> and inserting the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H315F45682A4645DC8E10007F45E7CBAB"><paragraph commented="no" display-inline="no-display-inline" id="H416A1F605B7248A48F6875CF8414508F"><enum>(1)</enum><header>In general</header><text>An entity</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H66F3048E7E6A401EBBD5DD793AD21258"><enum>(D)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HFDC8D19A5DE34BC89E8D0322E6DA3584"><paragraph commented="no" display-inline="no-display-inline" id="HDDD07D657510409EB15DFBE060CC9D59"><enum>(2)</enum><header>Transportation services</header><text>An entity receiving a grant under this section may use the funds for providing transportation for individuals to participate in an activity supported by a grant under this section, which transportation shall be to or from a place of work or a place where the individual is receiving vocational education or job training services or receiving services directly linked to treatment of or recovery from a substance use disorder.</text></paragraph><after-quoted-block>;</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H1D146ADD771C4FBEAE47F35FCCD50C53"><enum>(4)</enum><text>in subsection (j)—</text><subparagraph commented="no" display-inline="no-display-inline" id="H5B29B6EEAC1A49548C44566E517A4B77"><enum>(A)</enum><text display-inline="yes-display-inline">in paragraph (1), by inserting <quote>for each grant cycle</quote> after <quote>grant period</quote>; and</text></subparagraph><subparagraph id="HFDA61B9656414200B20699895D99F4F3" commented="no"><enum>(B)</enum><text>in paragraph (2)—</text><clause commented="no" display-inline="no-display-inline" id="H32AE55B8762B4DA4963C7652E663FCD2"><enum>(i)</enum><text display-inline="yes-display-inline">in the matter preceding subparagraph (A)—</text><subclause commented="no" display-inline="no-display-inline" id="H3C6148A7D8254A8BBE7F05F54A5A0121"><enum>(I)</enum><text display-inline="yes-display-inline">by striking <quote>the preliminary report</quote> and inserting <quote>each preliminary report</quote>; and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H5052F22D93CB48B3A37820BA41A07B69"><enum>(II)</enum><text>by inserting <quote>for the grant cycle</quote> after <quote>final report</quote>; and</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="H85916E6C6A0E46B9A11C2F02AEB04761"><enum>(ii)</enum><text>in subparagraph (A), by striking <quote>(g)(3)</quote> and inserting <quote>(g)(1)(C)</quote>; and</text></clause></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H0BC894B3F62E4987886E0F5B33822807"><enum>(5)</enum><text>in subsection (k), by striking <quote>$5,000,000 for each of fiscal years 2019 through 2023</quote> and inserting <quote>$12,000,000 for each of fiscal years 2024 through 2028</quote>.</text></paragraph></section><section id="H695287BD7E0048EF95D1B7DFF2D5038C"><enum>115.</enum><header>Grant program for State and Tribal response to opioid use disorders</header><text display-inline="no-display-inline">Section 1003(b)(4)(A) of the 21st Century Cures Act (42 U.S.C. 290ee–3a(b)(4)(A)) is amended after <quote>which may include drugs or devices approved, cleared, or otherwise legally marketed under the Federal Food, Drug, and Cosmetic Act</quote> by inserting <quote>or fentanyl or xylazine test strips</quote>.</text></section><section id="HE922CA0D0AEB4271BC49D237B48B59FD"><enum>116.</enum><header>References to opioid overdose reversal agents in HHS grant programs</header><subsection id="HF36DBDDDA51F4966A9536461F945653C"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services shall ensure that, whenever the Department of Health and Human Services issues a regulation, guidance, or other document for any grant program addressing opioid misuse and use disorders, any reference to an opioid overdose reversal agent (such as a reference to naloxone) is inclusive of any opioid overdose reversal agent that has been approved or otherwise authorized for use by the Food and Drug Administration.</text></subsection><subsection id="HFC3D599FBDAE4482BEE1661B49CCE9C5" commented="no"><enum>(b)</enum><header>Existing references</header><paragraph id="H5CE6A0BF61FE4AEB8F507AAEC647E686" commented="no"><enum>(1)</enum><header>Update</header><text>Not later than the end of calendar year 2023, the Secretary of Health and Human Services shall update all references described in paragraph (2) to be inclusive of any opioid overdose reversal agent that has been approved or otherwise authorized for use by the Food and Drug Administration.</text></paragraph><paragraph id="H55A59D2E14F74781A71B15BECAA4C209" commented="no"><enum>(2)</enum><header>References</header><text>A reference described in this paragraph is any reference to an opioid overdose reversal agent (such as naloxone) in any regulation, guidance, or other document of the Department of Health and Human Services that—</text><subparagraph id="HA4A57546EBC9434A979EF4457B9E11D8" commented="no"><enum>(A)</enum><text>was issued before the date of enactment of this Act; and</text></subparagraph><subparagraph id="HF26D20488C354D279CD03FE05B80E6A5" commented="no"><enum>(B)</enum><text>is for—</text><clause id="HFA35B441652C4118B421AB27BD6E1A05" commented="no"><enum>(i)</enum><text display-inline="yes-display-inline">the grant program for State and Tribal response to opioid use disorders under section 1003 of the 21st Century Cures Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290ee-3">42 U.S.C. 290ee–3</external-xref> note; commonly referred to as <quote>State Opioid Response Grants</quote> and <quote>Tribal Opioid Response Grants</quote>); or</text></clause><clause id="H7DCF4582BB464FFBB2AAC8D817319B9A" commented="no"><enum>(ii)</enum><text>the grant program for priority substance use disorder prevention needs of regional and national significance under section 516 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290bb-22">42 U.S.C. 290bb–22</external-xref>).</text></clause></subparagraph></paragraph></subsection></section><section id="H72237F8A325841CD95A18CDF20D4B538" section-type="subsequent-section"><enum>117.</enum><header>Addressing other concurrent substance use disorders through grant program for State and Tribal response to opioid use disorders</header><subsection id="H9DC0BA7BC75540299DBC272B11C05A90"><enum>(a)</enum><header>Additional use of funds</header><text display-inline="yes-display-inline">Section 1003(b) of the 21st Century Cures Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290ee-3">42 U.S.C. 290ee–3</external-xref> note) is amended by adding at the end the following:</text><quoted-block style="OLC" id="H25140B19458F4B8C97BAA529FD4D4A91" display-inline="no-display-inline"><paragraph id="H4B109A291ECB4936801F04880BD0885F"><enum>(5)</enum><header>Other concurrent substance use disorders</header><text display-inline="yes-display-inline">The Secretary may authorize the recipient of a grant under this subsection, in addition to using the grant for activities described in paragraph (4) with respect to opioid misuse and use disorders and stimulant misuse and use disorders, to use the grant to for similar activities with respect to other concurrent substance use disorders.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H54CF99069AB44A9EA2C9DC6D2AFDDD3E"><enum>(b)</enum><header>Annual report to Congress</header><text display-inline="yes-display-inline">Section 1003(f) of the 21st Century Cures Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290ee-3">42 U.S.C. 290ee–3</external-xref> note) is amended—</text><paragraph id="H0BC11CD73FBD4689A352BDB6166D7757"><enum>(1)</enum><text>in paragraph (2), strike <quote>and</quote> at the end;</text></paragraph><paragraph id="H72305758DA89462C975C518A0BCF34AE"><enum>(2)</enum><text>in paragraph (3), strike the period at the end and insert a semicolon; and</text></paragraph><paragraph id="HB1B3697C85F8422C9727D63568D90058"><enum>(3)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" id="H2AE769796DF54434AD431E5619372551" display-inline="no-display-inline"><paragraph id="HB02EB166505642DE86B9E0EE35A5A628"><enum>(4)</enum><text display-inline="yes-display-inline">the amount of funds each State that receiving a grant under subsection (b) received for the 12-month grant cycle covered by the report;</text></paragraph><paragraph id="HC40FA9012EDF45A2BDDC39AF1EEFA5A0"><enum>(5)</enum><text display-inline="yes-display-inline">the amount of grant funds each such State spent for such grant cycle, disaggregated by the uses for which such funds were spent, including each allowable use under paragraphs (4) and (5) of subsection (b);</text></paragraph><paragraph id="H1EAB2443083045B08F69F7538FE3E604"><enum>(6)</enum><text display-inline="yes-display-inline">how many such States for such grant cycle did not spend the all of the grant funds before such grant cycle expired;</text></paragraph><paragraph id="HE7DF6108CED64337884FE5A8900717B5"><enum>(7)</enum><text display-inline="yes-display-inline">how many such States for such grant cycle requested waivers to extend the grant cycle; and</text></paragraph><paragraph id="HF3398D8D2C2A43F68D698BBB5BB8ECE9"><enum>(8)</enum><text display-inline="yes-display-inline">challenges for such States to spend all of the funds allocated and the reason for such challenges, including to what extent reporting requirements or other requirements placed an increased burden on the ability of such States to spend all of the funds.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="HDB947C3BDE144CE9BFAEBD2D7C602DF5"><enum>(c)</enum><header>Other concurrent substance use disorders defined</header><text display-inline="yes-display-inline">Section 1003(h) of the 21st Century Cures Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290ee-3">42 U.S.C. 290ee–3</external-xref> note) is amended—</text><paragraph id="H13C90121887A4821B35DEFE961E7AB30"><enum>(1)</enum><text>by redesignating paragraphs (2) through (4) as paragraphs (3) through (5); and</text></paragraph><paragraph id="HD26D11712E534EA094CFF34A6B515796"><enum>(2)</enum><text>by inserting before paragraph (3), as redesignated, the following:</text><quoted-block style="OLC" id="H2C8AF9AEBC0F4A0A8B46EE60FC3EC261" display-inline="no-display-inline"><paragraph id="H77C83CA444314E329ECE90CBF6886F0D"><enum>(2)</enum><header>Other concurrent substance use disorders</header><text display-inline="yes-display-inline">The term <term>other substance use disorders</term> includes alcohol use disorders co-occurring with opioid misuse and use disorders and alcohol use disorders co-occurring with stimulant misuse and use disorders, including polydrug use and alcohol use disorder.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H1D58A0B3DC2645CD832CAA3E0C3CEDCB"><enum>(d)</enum><header>Rule of construction</header><text display-inline="yes-display-inline">Nothing in this Act or the amendments made by this Act shall be construed to change the allocation of funds among grantees pursuant to the minimum allocations and formula methodology under section 1003 of the 21st Century Cures Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290ee-3">42 U.S.C. 290ee–3</external-xref> note). </text></subsection></section><section id="HEB669F4F64694637B785AC03DDAD089F"><enum>118.</enum><header>Providing for a study on the effects of remote monitoring on individuals who are prescribed opioids</header><subsection id="HF75E66A75F87476E8E54F55EB221F91F"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 18 months after the date of enactment of this Act, the Comptroller General of the United States shall conduct a study and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions and the Committee on Finance of the Senate a report on the use of remote monitoring with respect to individuals who are prescribed opioids.</text></subsection><subsection id="H573ACF019512469180C8716B88A782D6"><enum>(b)</enum><header>Report</header><text>The report described in subsection (a) shall include—</text><paragraph id="HF81899845DF149FBA851BC734A59D574"><enum>(1)</enum><text>an assessment of scientific evidence related to the efficacy, individual outcomes, and potential cost savings associated with remote monitoring for individuals who are prescribed opioids compared to such individuals who are not so monitored;</text></paragraph><paragraph id="H93FC047DC61B4410869014A638C1DD2E"><enum>(2)</enum><text>an assessment of the current prevalence of remote monitoring for individuals who are prescribed opioids, including the use of such monitoring for such individuals in other countries; and</text></paragraph><paragraph id="H8FC4712E5B5549E1B87038CB7C604B41"><enum>(3)</enum><text>recommendations to improve availability, access, and coverage for remote monitoring for individuals who are prescribed opioids, including through changes to Federal health care programs (as defined in section 1128B of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1320a-7b">42 U.S.C. 1320a–7b</external-xref>)) and, if determined appropriate by the Comptroller General, an identification of cohorts of individuals who stand to benefit the most from remote monitoring when prescribed opioids.</text></paragraph></subsection></section></title><title id="H77197CC1DFFA4964B8F5BB7714B88534"><enum>II</enum><header>Controlled Substances</header><section id="HF5B4BB05D8C044D6A4E86366279AA9BC" section-type="subsequent-section"><enum>201.</enum><header>Delivery of certain substances by a pharmacy to an administering practitioner</header><text display-inline="no-display-inline">Paragraph (2) of section 309A(a) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/829a">21 U.S.C. 829a(a)</external-xref>) is amended to read as follows:</text><quoted-block style="OLC" id="H0726015B0A914F88B45ABD23306854AA" display-inline="no-display-inline"><paragraph id="H07EC13C80DD449A38FF4525CD75C0D35"><enum>(2)</enum><text display-inline="yes-display-inline">the controlled substance is a drug in schedule III, IV, or V that is, pursuant to the approval or licensure of such drug under the Federal Food, Drug, and Cosmetic Act or section 351 of the Public Health Service Act, to be administered by, or under the supervision of, the practitioner;</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></section><section id="H52ED9FA9D3014132AC29F099A828BB26"><enum>202.</enum><header>Reviewing the scheduling of approved products containing a combination of buprenorphine and naloxone</header><subsection id="H7F9F60B267084E61B4B6A5D7D23D8C58"><enum>(a)</enum><header>Secretary of HHS</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services shall, consistent with the requirements and procedures set forth in sections 201 and 202 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/811">21 U.S.C. 811</external-xref>; 812)—</text><paragraph id="H9A9A3FF0BD1F452D88FF2A72916AB6A0"><enum>(1)</enum><text display-inline="yes-display-inline">review the relevant data pertaining to the scheduling of products containing a combination of buprenorphine and naloxone that have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>); and</text></paragraph><paragraph id="HEF4A11CCC57E4DED976554A102DDFC59"><enum>(2)</enum><text display-inline="yes-display-inline">if appropriate, request that the Attorney General initiate rulemaking proceedings to revise the schedules accordingly with respect to such products.</text></paragraph></subsection><subsection id="HC263E48F1AAF497FB79D4360325D9BF4"><enum>(b)</enum><header>Attorney General</header><text display-inline="yes-display-inline">The Attorney General shall review any request made by the Secretary of Health and Human Services under subsection (a)(2) and determine whether to initiate proceedings to revise the schedules in accordance with the criteria set forth in sections 201 and 202 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/811">21 U.S.C. 811</external-xref>; 812).</text></subsection></section><section id="H76CA7AAB298A4E95B9AC07AA01C70084"><enum>203.</enum><header>Combating illicit xylazine</header><subsection id="HD2FD4B5D87674C86BE013DC9547D9A30"><enum>(a)</enum><header>Definitions</header><paragraph id="H602754F8664D4E1CBFC77DE77884B38A" commented="no" display-inline="no-display-inline"><enum>(1)</enum><header display-inline="yes-display-inline">In general</header><text>In this section, the term <term>xylazine</term> has the meaning given the term in paragraph (60) of section 102 of the Controlled Substances Act, as added by paragraph (2).</text></paragraph><paragraph id="H60E571423CFC4786B3A5162D54F12124" commented="no" display-inline="no-display-inline"><enum>(2)</enum><header>Controlled Substances Act</header><text display-inline="yes-display-inline">Section 102 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/802">21 U.S.C. 802</external-xref>) is amended—</text><subparagraph id="H91893AF1F2674A308507ED7E06BCE8CC" commented="no" display-inline="no-display-inline"><enum>(A)</enum><text display-inline="yes-display-inline">by redesignating the second paragraph (57) (relating to serious drug felony) and paragraph (58) as paragraphs (58) and (59), respectively;</text></subparagraph><subparagraph id="H41C67A1DDDA34AA19D41116CB0193089"><enum>(B)</enum><text>by moving the margin of paragraph (57) 2 ems to the left;</text></subparagraph><subparagraph id="H29793B40EC1E43E981E2DE256EDA325A"><enum>(C)</enum><text>by moving the margins of paragraphs (58) and (59), as redesignated, 2 ems to the left; and</text></subparagraph><subparagraph id="H790193824FD840A483FC7158FBD46263" commented="no" display-inline="no-display-inline"><enum>(D)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H287778A8AF364E2390ACA77B6E23D43D"><paragraph commented="no" display-inline="no-display-inline" id="H8908C1D8689642B0AEA2446CC4E9DB07" indent="up1"><enum>(60)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="H97BF1C214DBC4FF3B19CEDD14784A952"><enum>(A)</enum><text display-inline="yes-display-inline">The term <quote>xylazine</quote> means the substance xylazine as well as its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible.</text></subparagraph><subparagraph id="H98E93F3EEBCC44BAB032B2702A4D7A02" indent="up1"><enum>(B)</enum><text>Except as provided in subparagraph (E), such term does not include a substance described in subparagraph (A) to the extent—</text><clause id="H7CB7E55668694A298F0F11087A4DB339"><enum>(i)</enum><text display-inline="yes-display-inline">such substance is used or intended for use in animals other than humans and is an animal drug that has been approved by the Secretary of Health and Human Services under section 512 of the Federal Food, Drug, and Cosmetic Act, conditionally approved under section 571 of such Act, index listed under section 573 of such Act, or subject to an exemption for investigational use under section 512(j) of such Act, and such use or intended use conforms to the approved application or index listing, including the manufacturing, importation, holding, or distribution for such use;</text></clause><clause id="HABC20BADAAB6457988B3FDCF9687246E"><enum>(ii)</enum><text display-inline="yes-display-inline">such substance is used or intended for use in animals other than humans as permitted under section 512(a)(4) of the Federal Food, Drug, and Cosmetic Act;</text></clause><clause id="H68018D39AEE44E75A78BE397E64B47F8"><enum>(iii)</enum><text>such substance is manufactured, imported, held, distributed, or used—</text><subclause id="HECB22B60F5C343978A8C4D360C7436DA"><enum>(I)</enum><text display-inline="yes-display-inline">as an active pharmaceutical ingredient for manufacturing an animal drug approved under section 512 of the Federal Food, Drug, and Cosmetic Act, conditionally approved under section 571 of such Act, index listed under section 573 of the such Act, or subject to an exemption for investigational use under section 512(j) of such Act; or</text></subclause><subclause id="H611A3120A4BA4D618686ECB805773EC8"><enum>(II)</enum><text display-inline="yes-display-inline">as a bulk chemical for pharmaceutical compounding of a new animal drug (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act) by or under the direct supervision of a licensed pharmacist or by or on the lawful written or oral order of a licensed veterinarian within the context of a veterinarian-client-patient relationship, as defined by the Secretary of Health and Human Services;</text></subclause></clause><clause id="H708609E62020426DBBB9EBC8393926F7"><enum>(iv)</enum><text>such substance is held or used as a compounded new animal drug described in clause (iii)(II);</text></clause><clause id="HA5BE845B590D4D2996B12732CCDC1D7E"><enum>(v)</enum><text display-inline="yes-display-inline">such substance is otherwise used or intended for use in animals other than humans, and such use is approved or otherwise authorized under the Federal Food, Drug, and Cosmetic Act provided any such use conforms to such approval or authorization;</text></clause><clause id="H49CA52CC6EB8403FA06C2E8575461CC9"><enum>(vi)</enum><text>such substance is subject to an exemption for investigational use under section 505(i) or 520(g) of the Federal Food, Drug, and Cosmetic Act; </text></clause><clause id="HB619381E3BA64EA99EC3590CB3BC6D9D"><enum>(vii)</enum><text>such substance is imported, held, distributed, or used for the development, manufacturing, or performance of tests for detection of xylazine (including xylazine used as a control or calibration standard) by persons who are professionally, regularly, and lawfully engaged in such activities; or</text></clause><clause id="HEF6D8D3447EF48A6B52C59A139D26BF5"><enum>(viii)</enum><text display-inline="yes-display-inline">such substance is held, distributed, or used in a commercially manufactured test for the detection of xylazine, provided such test does not contain xylazine in a form that can be extracted.</text></clause></subparagraph><subparagraph id="H45F90222EA6C401588BA4B2D0D4D8CE7" indent="up1"><enum>(C)</enum><text display-inline="yes-display-inline">Notwithstanding subparagraph (B), the Attorney General may place any substance listed in such subparagraph on a schedule under section 202 in accordance with subsections (a) through (c) of section 201.</text></subparagraph><subparagraph id="HCB75000F7DD64BD0903D549731A19432" indent="up1"><enum>(D)</enum><text>Nothing in this paragraph shall be construed as a basis for inferring that a compounded animal drug is not a new animal drug subject to the requirements of section 512(a) of the Federal Food, Drug, and Cosmetic Act.</text></subparagraph><subparagraph id="H83F07529D2B040168D1F4A090575BABA" indent="up1"><enum>(E)</enum><text display-inline="yes-display-inline">If any person prescribes, dispenses, distributes, manufactures, or imports xylazine for human use, such person shall be considered to have prescribed, dispensed, distributed, manufactured, or imported xylazine not subject to an exclusion under subparagraph (B).</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph></subsection><subsection id="HE8926E1A687F4BC4B39F50BBB62CF846" commented="no"><enum>(b)</enum><header>Placement of xylazine on schedule III</header><text>Schedule III in section 202(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812(c)</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="H74C8EA25993342FB847BFEA34510E8A2" display-inline="no-display-inline"><subsection id="H67FA0D3B81814084A109104EE7F9A2BF" commented="no"><enum>(f)</enum><text display-inline="yes-display-inline">Xylazine.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H6C0EFD9899E64F69BF94901F615769FD"><enum>(c)</enum><header>Report to Congress on xylazine</header><paragraph id="HAFC18328C04844DC9ADAEFB37A30EF87"><enum>(1)</enum><header>Initial report</header><text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall submit to Congress a report on the prevalence of illicit use of xylazine in the United States and the impacts of such use, including—</text><subparagraph id="H124AB4E027CB40ACA3B244CDEF6BBDBA"><enum>(A)</enum><text>where the drug is being diverted;</text></subparagraph><subparagraph id="H3E0295E6381C4B339857D1919107CD9E"><enum>(B)</enum><text>where the drug is originating;</text></subparagraph><subparagraph id="HBEED7BD6F3E24D35BC2DF4C780AFA5FE"><enum>(C)</enum><text>whether any analogues to such drug present a substantial risk of abuse;</text></subparagraph><subparagraph id="H51EC90F636294F1492DEABE459C5B5B0"><enum>(D)</enum><text>whether and to what extent the illicit supply of xylazine derives from the licit supply chain; and</text></subparagraph><subparagraph id="H7727055BC3974734859DA210EEBEB74B"><enum>(E)</enum><text display-inline="yes-display-inline">recommendations for Congress with respect to whether xylazine should be transferred to another schedule under section 202 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812</external-xref>).</text></subparagraph></paragraph><paragraph id="H6AB5C7AF200E455783EAC897928EF0C1"><enum>(2)</enum><header>Additional report</header><text display-inline="yes-display-inline">Not later than 4 years after the date of enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall submit to Congress a report updating Congress on the prevalence of xylazine trafficking, misuse, and proliferation in the United States, including recommendations for Congress with respect to whether xylazine should be transferred to another schedule under section 202 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812</external-xref>) or removed from schedule III of such part.</text></paragraph></subsection></section><section id="HCA49109F12A8494AA315A98CA7AD5A0B"><enum>204.</enum><header>Technical corrections</header><text display-inline="no-display-inline">Effective as if included in the enactment of <external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref>—</text><paragraph id="H3E2BF8CE9C5B4566A6B1D4A2AE6293B5"><enum>(1)</enum><text>section 1252(a) of division FF of <external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref> is amended, in the matter being inserted into section 302(e) of the Controlled Substances Act, by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>;</text></paragraph><paragraph id="H588885A88801434590C3512F744BACBF"><enum>(2)</enum><text>section 1262 of division FF of <external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref> is amended—</text><subparagraph id="HE0D7D5490859482FBAC401C3F64CB578"><enum>(A)</enum><text>in subsection (a)—</text><clause id="H990669044B1B4C6A8432EE5CBC44D27D"><enum>(i)</enum><text>in the matter preceding paragraph (1), by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>;</text></clause><clause id="H79BDDE04A2894B88958D94F52C936C19"><enum>(ii)</enum><text>in the matter being stricken by subsection (a)(2), by striking <quote>(g)(1)</quote> and inserting <quote>(h)(1)</quote>; and</text></clause><clause id="H9806C1898F1E43AFA8750546EF7F3770"><enum>(iii)</enum><text>in the matter being inserted by subsection (a)(2), by striking <quote>(g) Practitioners</quote> and inserting <quote>(h) Practitioners</quote>; and</text></clause></subparagraph><subparagraph id="H60E372593DA54955A244994A53FC9357"><enum>(B)</enum><text>in subsection (b)—</text><clause id="H1705DC942F504F809DB123A61B858B94"><enum>(i)</enum><text>in the matter being stricken by paragraph (1), by striking <quote>303(g)(1)</quote> and inserting <quote>303(h)(1)</quote>;</text></clause><clause id="H93AA8BBB1811449C8AB59C31BC029AC6"><enum>(ii)</enum><text>in the matter being inserted by paragraph (1), by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>;</text></clause><clause id="H8B8F9A0EDD7841C6A70C6543CE9F1673"><enum>(iii)</enum><text>in the matter being stricken by paragraph (2)(A), by striking <quote>303(g)(2)</quote> and inserting <quote>303(h)(2)</quote>;</text></clause><clause id="H930167FFB6A2425A9202E495BEEB236F"><enum>(iv)</enum><text>in the matter being stricken by paragraph (3), by striking <quote>303(g)(2)(B)</quote> and inserting <quote>303(h)(2)(B)</quote>;</text></clause><clause id="H3223A7F194E9426D8CCE8020D89D31F0"><enum>(v)</enum><text>in the matter being stricken by paragraph (5), by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>; and</text></clause><clause id="H34D99F736765469CB9C0DFEBBF6E27C4"><enum>(vi)</enum><text>in the matter being stricken by paragraph (6), by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>; and</text></clause></subparagraph></paragraph><paragraph id="HEA4843F695C14B99A031A5D2020B30AE"><enum>(3)</enum><text display-inline="yes-display-inline">section 1263(b) of division FF of <external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref> is amended—</text><subparagraph id="HAA2259229D7E4B648FE98CEBA70B016A"><enum>(A)</enum><text>by striking <quote>303(g)(2)</quote> and inserting <quote>303(h)(2)</quote>; and</text></subparagraph><subparagraph id="HA9BE8B96F4FF462F83AA0B68106B59E4"><enum>(B)</enum><text>by striking <quote>(<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823(g)(2)</external-xref>)</quote> and inserting <quote>(<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823(h)(2)</external-xref>)</quote>. </text></subparagraph></paragraph></section></title><title id="HC591B937F13549E49190DE790096CD77"><enum>III</enum><header>Medicaid</header><section id="HF9A9409399EF4A129A7298457C98DA2A"><enum>301.</enum><header>Extending requirement for State Medicaid plans to provide coverage for medication-assisted treatment</header><subsection id="H7988B8022FC24D459DFE3CE93A83CDA4"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 1905 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396d">42 U.S.C. 1396d</external-xref>) is amended—</text><paragraph id="H11F4F858085A4D229FFA6C332FCBE7C1"><enum>(1)</enum><text>in subsection (a)(29), by striking <quote>for the period beginning October 1, 2020, and ending September 30, 2025,</quote> and inserting <quote>beginning on October 1, 2020,</quote>; and</text></paragraph><paragraph id="H742EE14FF11848D6B44A15EB0223E3E9"><enum>(2)</enum><text>in subsection (ee)(2), by striking <quote>for the period specified in such paragraph, if before the beginning of such period the State certifies to the satisfaction of the Secretary</quote> and inserting <quote>if such State certifies, not less than every 5 years and to the satisfaction of the Secretary,</quote>.</text></paragraph></subsection><subsection id="HDB9546FB553843BBA3B29E6208D4B484"><enum>(b)</enum><header>Conforming amendment</header><text display-inline="yes-display-inline">Section 1006(b)(4)(A) of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396a">42 U.S.C. 1396a</external-xref> note) is amended by striking <quote>, and before October 1, 2025</quote>.</text></subsection></section><section id="HF28D0703FBF149158705AAD741A2CD95" section-type="subsequent-section"><enum>302.</enum><header>Expanding required reports on T–MSIS substance use disorder data to include mental health condition data</header><subsection id="H57628E072F5E4DF48D71320C323F1F17"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 1015(a) of the SUPPORT for Patients and Communities Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1320d-2">42 U.S.C. 1320d–2</external-xref> note) is amended—</text><paragraph id="H20F7BB584F0D43ECBDF215B0F1F31942"><enum>(1)</enum><text>in the heading, by striking <quote><header-in-text level="subsection" style="OLC">substance use disorder data book</header-in-text></quote> and inserting <quote><header-in-text level="subsection" style="OLC">behavioral health data book</header-in-text></quote>; </text></paragraph><paragraph id="H40B224DFECEA4A17B10DB09F4D56C259"><enum>(2)</enum><text>in paragraph (2)—</text><subparagraph id="H16AB239D5FF14FEF880AAC81A8C1BA14"><enum>(A)</enum><text>in the matter preceding subparagraph (A), by inserting <quote>, including as updated in accordance with paragraph (3),</quote> after <quote>paragraph (1)</quote>;</text></subparagraph><subparagraph id="HAC1EB7DC092A48B580F2E2515F05EBEB"><enum>(B)</enum><text>in subparagraph (A), by inserting <quote>, mental health condition, or a mental health condition co-occurring with substance use disorder</quote> after <quote>substance use disorder</quote>;</text></subparagraph><subparagraph id="HDD7195F010ED45E8B218A537C42EF736"><enum>(C)</enum><text>in subparagraph (B), by inserting <quote>and mental health treatment services</quote> after <quote>substance use disorder treatment services</quote>;</text></subparagraph><subparagraph id="HE875EAF5CBDF4654970AD33BDC07AEBC"><enum>(D)</enum><text>in subparagraph (C)—</text><clause id="HDAC4ECA9E8FC43828EF5F0A4D7F2B4FA"><enum>(i)</enum><text>by inserting <quote>, mental health condition, or a mental health condition co-occurring with a substance use disorder diagnosis</quote> after <quote>substance use disorder diagnosis</quote>; and</text></clause><clause id="HB274E83D639744B3A50C716C627251DD"><enum>(ii)</enum><text>by inserting <quote>or mental health treatment services, respectively,</quote> after <quote>substance use disorder treatment services</quote>;</text></clause></subparagraph><subparagraph id="HF3B0D54930794E008A9B7F375FE50845"><enum>(E)</enum><text>in subparagraph (D), by inserting <quote>, mental health condition, or a mental health condition co-occurring with substance use disorder</quote> after <quote>substance use disorder diagnosis</quote>;</text></subparagraph><subparagraph id="H567FCD55D6B8435A9E1461124FDBCBE2"><enum>(F)</enum><text>in subparagraph (E), by inserting <quote>or mental health treatment</quote> after <quote>substance use disorder treatment</quote>; and</text></subparagraph><subparagraph id="HE8D58C572B784ECF8FBE5E3559DFCD68"><enum>(G)</enum><text>in subparagraph (F), by inserting <quote>, individuals with a mental health condition who receive mental health treatment services, and individuals with a co-occurring mental health condition and substance use disorder who receive substance use disorder treatment services and mental health treatment services,</quote> after <quote>substance use disorder treatment services</quote>; and</text></subparagraph></paragraph><paragraph id="H39B0918E5DE247E8AE1D617B7BF3E125"><enum>(3)</enum><text>in paragraph (3), by striking <quote>through 2024</quote>.</text></paragraph></subsection><subsection id="H333FF3216B37476694631A6971B3EBC9" commented="no"><enum>(b)</enum><header>Application</header><text display-inline="yes-display-inline">The amendments made by subsection (a)(1) shall apply beginning with respect to the first update made pursuant to section 1015(a)(3) of the SUPPORT for Patients and Communities Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1320d-2">42 U.S.C. 1320d–2</external-xref> note) after the date that is 12 months after the date of enactment of this Act.</text></subsection></section><section id="H39132D27809E43499EAD9EB0350021AE"><enum>303.</enum><header>Monitoring prescribing of antipsychotic medications</header><text display-inline="no-display-inline">Section 1902(oo) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396a">42 U.S.C. 1396a(oo)</external-xref>) is amended—</text><paragraph id="H5E9FE2E99E0A47618061E38F7D1EE714"><enum>(1)</enum><text>in paragraph (1)(B)—</text><subparagraph id="H388BFD99559D41B284C1053F92E388F9"><enum>(A)</enum><text>in the subparagraph heading, by striking <quote><header-in-text level="subparagraph" style="OLC">by children</header-in-text></quote>; and</text></subparagraph><subparagraph id="H350ACF1E93B043D2995DDE4333B337CB" commented="no"><enum>(B)</enum><text>by inserting <quote>, and beginning on the date that is 24 months after the date of enactment of the <short-title>Support for Patients and Communities Reauthorization Act</short-title>, individuals over the age of 18, individuals receiving home and community-based services (as defined in section 9817(a)(2)(B) of <external-xref legal-doc="public-law" parsable-cite="pl/117/2">Public Law 117–2</external-xref>), and individuals residing in institutional care settings (including nursing facilities and intermediate care facilities for individuals with intellectual disabilities) enrolled,</quote> after <quote>children enrolled</quote>; and </text></subparagraph></paragraph><paragraph id="H93D458FD2A4041AC92C9CF00DC1C0E7B"><enum>(2)</enum><text>in paragraph (3)—</text><subparagraph id="H14F8AE0E77D040F69923F9824C73473C"><enum>(A)</enum><text>in subparagraph (A)(ii), by striking <quote>is a resident</quote> and inserting <quote>subject to subparagraph (C), is a resident</quote>; and</text></subparagraph><subparagraph id="H11ADFE6BE1BA48198E22491B7A44EE97"><enum>(B)</enum><text>by adding at the end the following new subparagraph:</text><quoted-block style="OLC" id="H7A92A4E3C0BF440EBD4C86EB117E1810" display-inline="no-display-inline"><subparagraph id="HBD0814A1C21D4A7E9BE95E459A2EAD23" commented="no"><enum>(C)</enum><header>Application in case of program to monitor antipsychotic medications</header><text display-inline="yes-display-inline">Subparagraph (A)(ii) shall not apply to the drug review and utilization requirement described in paragraph (1)(B) with respect to an individual to whom such subparagraph applies by reason of the amendments made by section 303(1) of the <short-title>Support for Patients and Communities Reauthorization Act</short-title>.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph></section></title></legis-body></bill> 

